These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1649137)

  • 1. Detection of anti-Epstein-Barr-virus transactivator (ZEBRA) antibodies in sera from patients with nasopharyngeal carcinoma.
    Joab I; Nicolas JC; Schwaab G; de-Thé G; Clausse B; Perricaudet M; Zeng Y
    Int J Cancer; 1991 Jul; 48(5):647-9. PubMed ID: 1649137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analyses of the prognostic significance of the Epstein-Barr virus transactivator ZEBRA protein and diagnostic value of its two synthetic peptides in nasopharyngeal carcinoma.
    Dardari R; Menezes J; Drouet E; Joab I; Benider A; Bakkali H; Kanouni L; Jouhadi H; Benjaafar N; El Gueddari B; Hassar M; Khyatti M
    J Clin Virol; 2008 Feb; 41(2):96-103. PubMed ID: 18024156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes.
    Tedeschi R; Foong YT; Cheng HM; dePaoli P; Lehtinen T; Elfborg T; Dillner J
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1393-400. PubMed ID: 7540196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of IgA against Epstein-Barr virus BZLF-1 replication activator (ZEBRA) in sera of nasopharyngeal carcinoma patients with a recombinant ZEBRA protein.
    Shu CH; Tu TY; Lin LS; Ro LH; Lo MS; Huang CH; Chen KY; Liu WT
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jun; 62(6):350-5. PubMed ID: 10389292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
    Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
    Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of in situ hybridization using different nonisotopic probes for detection of Epstein-Barr virus in nasopharyngeal carcinoma and immunohistochemical correlation with anti-latent membrane protein antibody.
    Brousset P; Butet V; Chittal S; Selves J; Delsol G
    Lab Invest; 1992 Oct; 67(4):457-64. PubMed ID: 1331609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma.
    Mathew A; Cheng HM; Sam CK; Joab I; Prasad U; Cochet C
    Cancer Immunol Immunother; 1994 Jan; 38(1):68-70. PubMed ID: 8299121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A possible prognostic role of immunoglobulin-G antibody against recombinant Epstein-Barr virus BZLF-1 transactivator protein ZEBRA in patients with nasopharyngeal carcinoma.
    Yip TT; Ngan RK; Lau WH; Poon YF; Joab I; Cochet C; Cheng AK
    Cancer; 1994 Nov; 74(9):2414-24. PubMed ID: 7922994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr virus (EBV) replicative gene expression in tumour cells of AIDS-related non-Hodgkin's lymphoma in relation to CD4 cell number and antibody titres to EBV.
    Brousset P; Drouet E; Schlaifer D; Icart J; Payen C; Meggetto F; Marchou B; Massip P; Delsol G
    AIDS; 1994 May; 8(5):583-90. PubMed ID: 7914731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme-linked immunosorbent assay for antibodies to ZEBRA, an Epstein-Barr trans-activator.
    Maréchal V; Meyohas MC; Joab I; Gaha S; Giot JF; Sergeant A; Nicolas JC
    Res Virol; 1993; 144(5):397-404. PubMed ID: 8284517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of antibodies to the Epstein-Barr virus immediate early gene product ZEBRA by a new enzyme-linked immunosorbent assay.
    Yamauchi Y; Tachiband Y; Maeda A; Wakiguchi H; Usui M; Kurata T; Sairenji T
    Intervirology; 1998; 41(6):278-84. PubMed ID: 10325538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of anti-Epstein-Barr virus trans-activator (ZEBRA) antibodies in sera from patients with human immunodeficiency virus.
    Joab I; Triki H; de Saint Martin J; Perricaudet M; Nicolas JC
    J Infect Dis; 1991 Jan; 163(1):53-6. PubMed ID: 1845809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linear epitopes of the replication-activator protein of Epstein-Barr virus recognised by specific serum IgG in nasopharyngeal carcinoma.
    Cheng HM; Foong YT; AbuSamah AJ; Dillner J; Sam CK; Prasad U
    Cancer Immunol Immunother; 1995 Apr; 40(4):251-6. PubMed ID: 7750123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals.
    Zhu XX; Zeng Y; Wolf H
    Int J Cancer; 1986 May; 37(5):689-91. PubMed ID: 3009331
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
    Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
    Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Demonstration of IgG- and IgA-antibodies against Epstein-Barr virus-associated antigens with a microtiter enzyme immunoassay system. The determination of serum antibodies against the viral capsid antigen and the early antigen complex in the sera of tumor and infectious mononucleosis patients].
    Dölken G; Bitzer M; Bross KJ; Brugger W; Boldt C; Hirsch FW; Weitzmann U; Löhr GW
    Dtsch Med Wochenschr; 1984 Nov; 109(48):1837-43. PubMed ID: 6094138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum.
    Cheng WM; Chan KH; Chen HL; Luo RX; Ng SP; Luk W; Zheng BJ; Ji MF; Liang JS; Sham JS; Wang DK; Zong YS; Ng MH
    Int J Cancer; 2002 Feb; 97(4):489-92. PubMed ID: 11802211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of elevated antibody titers to Epstein-Barr virus in patients with uveitis.
    Touge C; Agawa H; Sairenji T; Inoue Y
    Arch Virol; 2006 May; 151(5):895-903. PubMed ID: 16362642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus.
    Rowe M; Finke J; Szigeti R; Klein G
    J Gen Virol; 1988 Jun; 69 ( Pt 6)():1217-28. PubMed ID: 2838572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, tonsillar carcinoma and control groups.
    Oberender H; Nowak R; Donner A; Kunkel M; Gärtner L; Scholtz HJ
    Acta Virol; 1983 May; 27(3):277-81. PubMed ID: 6138990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.